Advertisement

Reactions Weekly

, Volume 1154, Issue 1, pp 2–2 | Cite as

Prescribing of bicalutamide should be restricted to patients at high risk of disease progression

News item
  • 13 Downloads

Keywords

Public Health Adverse Effect High Risk Prostate Cancer Medicinal Product 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

REFERENCE

  1. 1.
    European Medicines Agency.Questions and answers on bicalutamide 150 mg tablets. Internet Document: [2 pages], 24 May 2007. Available from: URL: http://www.emea.europa.eu

Copyright information

© Adis International limited or Adis Data Information BV 2007

Personalised recommendations